{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:49:05Z","timestamp":1790182145500,"version":"4.1.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["Sche 341\/19-1"],"award-info":[{"award-number":["Sche 341\/19-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["Sche 341\/19-2"],"award-info":[{"award-number":["Sche 341\/19-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.neuropharm.2014.12.008","type":"journal-article","created":{"date-parts":[[2014,12,20]],"date-time":"2014-12-20T04:33:02Z","timestamp":1419049982000},"page":"83-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"PA","title":["Neurobehavioral consequences of small molecule-drug immunosuppression"],"prefix":"10.1016","volume":"96","author":[{"given":"Katharina","family":"B\u00f6sche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Weissenborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Christians","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Engler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Schedlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hadamitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2014.12.008_bib1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(87)90294-7","article-title":"Neurological complications following liver transplantation","volume":"1","author":"Adams","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.20.2.485","article-title":"Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma","volume":"20","author":"Ahles","year":"2002","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib3","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/j.1600-6143.2008.02399.x","article-title":"Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation","volume":"8","author":"Al-Massarani","year":"2008","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.crohns.2010.10.005","article-title":"Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding","volume":"5","author":"Angelberger","year":"2011","journal-title":"J.\u00a0Crohn's Colitis"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.98.1.136","article-title":"A\u00a0role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt","volume":"98","author":"Aoki","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib147","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1517\/14656566.2.3.409","article-title":"The pharmacology of methotrexate","volume":"2","author":"Barnhart","year":"2001","journal-title":"Expert Opin. Pharmacother"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib6","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0041-1345(96)00481-2","article-title":"The downstream consequences of calcineurin inhibition","volume":"29","author":"Batiuk","year":"1997","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1432-2277.2000.tb01004.x","article-title":"Neurotoxicity of calcineurin inhibitors: impact and clinical management","volume":"13","author":"Bechstein","year":"2000","journal-title":"Transpl. Int."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1124\/jpet.111.188169","article-title":"Immunophyllin ligands show differential effects on alcohol self-administration in C57BL mice","volume":"341","author":"Beresford","year":"2012","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jama.2014.8342","article-title":"Avoiding nocebo effects to optimize treatment outcome","volume":"312","author":"Bingel","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.nlm.2007.12.004","article-title":"Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidation","volume":"90","author":"Blundell","year":"2008","journal-title":"Neurobiol. Learn Mem."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib11","article-title":"Perspectives in immunopharmacology: the future of immunosuppression","author":"Boraschi","year":"2013","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0006-8993(02)03474-1","article-title":"Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity","volume":"956","author":"Borlongan","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib14","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-2202-12-124","article-title":"Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications","volume":"12","author":"Briones","year":"2011","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1399-0012.2000.140101.x","article-title":"Central nervous system complications in liver transplant recipients\u2013incidence, timing, and long-term follow-up","volume":"14","author":"Bronster","year":"2000","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib17","first-page":"63","article-title":"Neurologic complications of orthotopic liver transplantation","volume":"61","author":"Bronster","year":"1994","journal-title":"Mt. Sinai J. Med."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib18","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.V1341073","article-title":"First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients","volume":"13","author":"Budde","year":"2002","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"issue":"Suppl.\u00a017","key":"10.1016\/j.neuropharm.2014.12.008_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1399-0012.2006.00596.x","article-title":"FTY720 (fingolimod) in renal transplantation","volume":"20","author":"Budde","year":"2006","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2012.11.003","article-title":"Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex","volume":"67","author":"Cambiaghi","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0306-4530(01)00030-0","article-title":"Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy","volume":"26","author":"Capuron","year":"2001","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.pnpbp.2012.08.001","article-title":"Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress","volume":"40","author":"Chandran","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib23","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1016\/S0041-1345(01)02510-6","article-title":"Cyclosporine-associated encephalopathy: a case report and literature review","volume":"33","author":"Chang","year":"2001","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4161\/oxim.3.6.14787","article-title":"Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders","volume":"3","author":"Chong","year":"2010","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/sj.bjp.0705939","article-title":"Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors","volume":"143","author":"Christians","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib26","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1158\/1078-0432.CCR-11-2000","article-title":"Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy","volume":"18","author":"Christie","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.brainresbull.2008.03.005","article-title":"Antidepressive-like effects of rapamycin in animal models: implications for mTOR inhibition as a new target for treatment of affective disorders","volume":"76","author":"Cleary","year":"2008","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ana.22426","article-title":"Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis","volume":"69","author":"Cohen","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","article-title":"mTOR signaling and drug development in cancer","volume":"7","author":"Dancey","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nrclinonc.2012.88","article-title":"Translational approaches to treatment-induced symptoms in cancer patients","volume":"9","author":"Dantzer","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJM198710013171404","article-title":"Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol","volume":"317","author":"de Groen","year":"1987","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1592\/phco.28.1.136","article-title":"Depressive disorder associated with mycophenolate mofetil","volume":"28","author":"Draper","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0024-3205(90)90582-C","article-title":"Effect of cyclosporin A on rat kidney catecholamines","volume":"47","author":"Duruibe","year":"1990","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuropharm.2012.05.015","article-title":"From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches","volume":"68","author":"Ehninger","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib37","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3923","article-title":"The placebo response in medicine: minimize, maximize or personalize?","volume":"12","author":"Enck","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nbd.2006.12.003","article-title":"Rapamycin is a neuroprotective treatment for traumatic brain injury","volume":"26","author":"Erlich","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-3083.1991.tb03746.x","article-title":"Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in\u00a0vitro: role of deoxyguanosine nucleotide depletion","volume":"33","author":"Eugui","year":"1991","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib41","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.psyneuen.2012.03.019","article-title":"Neuroplastic changes in depression: a role for the immune system","volume":"37","author":"Eyre","year":"2012","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00007890-198908000-00025","article-title":"Central nervous system toxicity of cyclosporine in a rat model","volume":"48","author":"Famiglio","year":"1989","journal-title":"Transplantation"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.pbb.2010.08.019","article-title":"Single high dose treatment with methotrexate causes long-lasting cognitive dysfunction in laboratory rodents","volume":"97","author":"Fardell","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0004867412463090","article-title":"Fingolimod exacerbated affective psychosis?","volume":"47","author":"Fitzpatrick","year":"2013","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib45","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.transproceed.2005.02.101","article-title":"Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation","volume":"37","author":"Forgacs","year":"2005","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.107.127183","article-title":"Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis","volume":"323","author":"Foster","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbr.2011.09.013","article-title":"Preserved learning and memory in mice following chemotherapy: 5-Fluorouracil and doxorubicin single agent treatment, doxorubicin-cyclophosphamide combination treatment","volume":"226","author":"Fremouw","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib48","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0024-3205(02)02250-6","article-title":"Cyclosporine A-increased nitric oxide production in the rat dorsal hippocampus mediates convulsions","volume":"72","author":"Fujisaki","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.neuroscience.2008.08.060","article-title":"A\u00a0novel electrophysiological model of chemotherapy-induced cognitive impairments in mice","volume":"157","author":"Gandal","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/msc.171","article-title":"Psychological well-being in rheumatoid arthritis: a review of the literature","volume":"8","author":"Gettings","year":"2010","journal-title":"Musculoskelet. Care"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib51","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/TP.0b013e3181817dd7","article-title":"Psychosocial profiles after transplantation: a 24-month follow-up of heart, lung, liver, kidney and allogeneic bone-marrow patients","volume":"86","author":"Goetzmann","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib52","first-page":"477","article-title":"Psychological response and quality of life after transplantation: a comparison between heart, lung, liver and kidney recipients","volume":"138","author":"Goetzmann","year":"2008","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12311-013-0528-1","article-title":"Leukoencephalopathy due to oral methotrexate","volume":"13","author":"Gonzalez-Suarez","year":"2014","journal-title":"Cerebellum"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib54","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/6365","article-title":"Learning enhances adult neurogenesis in the hippocampal formation","volume":"2","author":"Gould","year":"1999","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib55","doi-asserted-by":"crossref","first-page":"pe24","DOI":"10.1126\/scisignal.267pe24","article-title":"The pharmacology of mTOR inhibition","volume":"2","author":"Guertin","year":"2009","journal-title":"Sci. Signal"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbr.2014.06.056","article-title":"Acute systemic rapamycin induces neurobehavioral alterations in rats","volume":"273C","author":"Hadamitzky","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib57","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nn.3728","article-title":"Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory","volume":"17","author":"Hait","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib58","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/0192623311427569","article-title":"Small molecule immunomodulatory drugs: challenges and approaches for balancing efficacy with toxicity","volume":"40","author":"Haley","year":"2012","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib59","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib60","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0304-3940(03)00016-8","article-title":"Cyclosporine A inhibits acetylcholinesterase activity in selected parts of the rat brain","volume":"339","author":"Herink","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tins.2009.11.003","article-title":"mTOR signaling: at the crossroads of plasticity, memory and disease","volume":"33","author":"Hoeffer","year":"2010","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib62","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/brain\/99.4.673","article-title":"The neurological complications of cardiac transplantation","volume":"99","author":"Hotson","year":"1976","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib63","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cncr.22368","article-title":"Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy","volume":"109","author":"Inagaki","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib64","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1188\/05.ONF.1151-1163","article-title":"Potential mechanisms for chemotherapy-induced impairments in cognitive function","volume":"32","author":"Jansen","year":"2005","journal-title":"Oncol. Nurs. Forum"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib65","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00520-010-0997-4","article-title":"A\u00a0prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients","volume":"19","author":"Jansen","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib66","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.pnpbp.2011.05.010","article-title":"The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder","volume":"35","author":"Jernigan","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib67","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clim.2004.09.001","article-title":"The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules","volume":"114","author":"Johnston","year":"2005","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib68","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neulet.2012.08.087","article-title":"The immunosuppressant cyclosporin A inhibits recurrent seizures in an experimental model of temporal lobe epilepsy","volume":"529","author":"Jung","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib69","first-page":"3082","article-title":"Role of cyclosporine: present and future","volume":"26","author":"Kahan","year":"1994","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib70","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00007890-198702000-00007","article-title":"Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years","volume":"43","author":"Kahan","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib71","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A\u00a0placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib72","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/ard.2008.102822","article-title":"Methotrexate: the gold standard without standardisation","volume":"68","author":"Kay","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib73","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.conb.2004.03.001","article-title":"Functional significance of adult neurogenesis","volume":"14","author":"Kempermann","year":"2004","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib74","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/NCC.0b013e318233a811","article-title":"Common biological pathways underlying the psychoneurological symptom cluster in cancer patients","volume":"35","author":"Kim","year":"2012","journal-title":"Cancer Nurs."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2014.08.027","article-title":"Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients","author":"Kivity","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib76","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1021\/tx900351q","article-title":"Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism","volume":"23","author":"Klawitter","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib77","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11011-008-9100-y","article-title":"Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats","volume":"23","author":"Konat","year":"2008","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib78","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-005-7093-3","article-title":"Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy","volume":"94","author":"Kreukels","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ceb.2009.01.016","article-title":"Optimal targeting of the mTORC1 kinase in human cancer","volume":"21","author":"Lane","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib80","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1016\/j.transproceed.2009.08.050","article-title":"Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement","volume":"41","author":"Lang","year":"2009","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib81","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-05-1286","article-title":"Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy","volume":"12","author":"Lee","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib82","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1161\/01.CIR.0000149745.83186.89","article-title":"Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs","volume":"110","author":"Lindenfeld","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib83","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1161\/01.CIR.0000150332.42276.69","article-title":"Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs","volume":"110","author":"Lindenfeld","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib84","doi-asserted-by":"crossref","first-page":"e21445","DOI":"10.1371\/journal.pone.0021445","article-title":"The effects of cyclophosphamide on hippocampal cell proliferation and spatial working memory in rat","volume":"6","author":"Lyons","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib85","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbr.2007.04.003","article-title":"Cancer chemotherapy impairs contextual but not cue-specific fear memory","volume":"181","author":"Macleod","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib86","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ctrv.2013.02.005","article-title":"mTOR inhibitors in advanced breast cancer: ready for prime time?","volume":"39","author":"Martin","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib87","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1600-6143.2009.02998.x","article-title":"Neurological complications following adult lung transplantation","volume":"10","author":"Mateen","year":"2010","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib88","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.wnl.0000327609.57688.ea","article-title":"FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis","volume":"71","author":"Mehling","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib89","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0162-3109(00)00190-9","article-title":"The use of mycophenolate mofetil in transplant recipients","volume":"47","author":"Mele","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib90","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1124\/dmd.105.009001","article-title":"Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses","volume":"34","author":"Meno-Tetang","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib91","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1126\/science.124.3211.67","article-title":"Walter S. Adams, Observer of Sun and Stars","volume":"124","author":"Merill","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib92","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1200\/JCO.2007.10.7805","article-title":"Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer","volume":"26","author":"Miller","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib93","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1161\/01.CIR.94.6.1209","article-title":"Cyclosporine-associated neurotoxicity. The need for a better guide for immunosuppressive therapy","volume":"94","author":"Miller","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib94","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.biopsych.2014.03.009","article-title":"Calcineurin downregulation in the amygdala is sufficient to induce anxiety-like and depression-like behaviors in C57BL\/6J male mice","volume":"75","author":"Mineur","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib95","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2353\/ajpath.2008.080478","article-title":"Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod","volume":"173","author":"Miron","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib96","doi-asserted-by":"crossref","first-page":"8987","DOI":"10.1073\/pnas.1432926100","article-title":"Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia","volume":"100","author":"Miyakawa","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib97","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/ki.1996.28","article-title":"The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients","volume":"49","author":"Murgia","year":"1996","journal-title":"Kidney Int."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib98","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJM200103293441303","article-title":"Paroxetine for the prevention of depression induced by high-dose interferon alfa","volume":"344","author":"Musselman","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib99","first-page":"980301","article-title":"Methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"2014","author":"Nassar","year":"2014","journal-title":"J.\u00a0Transpl."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/13803395.2011.614599","article-title":"The cerebellum and neuropsychological functioning: a critical review","volume":"34","author":"O'Halloran","year":"2012","journal-title":"J.\u00a0Clin. Exp. Neuropsychol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib101","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1017\/S1461145711001799","article-title":"Neurobehavioural activation during peripheral immunosuppression","volume":"16","author":"Pacheco-Lopez","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib102","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0272-6386(12)80300-3","article-title":"Severe neurologic toxicity induced by cyclosporine A in three renal transplant patients","volume":"18","author":"Palmer","year":"1991","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib103","doi-asserted-by":"crossref","first-page":"12977","DOI":"10.1523\/JNEUROSCI.4209-06.2006","article-title":"Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons","volume":"26","author":"Parsons","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib104","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.immuni.2007.11.017","article-title":"S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress","volume":"28","author":"Pham","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib105","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.comppsych.2013.05.010","article-title":"Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs","volume":"54","author":"Pinho de Oliveira Ribeiro","year":"2013","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib106","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00007890-199101000-00003","article-title":"RS-61443\u2013a new, potent immunosuppressive agent","volume":"51","author":"Platz","year":"1991","journal-title":"Transplantation"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib107","first-page":"934","article-title":"Neurologic abnormalities and mortality in rats treated with cyclosporine A","volume":"20","author":"Racusen","year":"1988","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib108","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0024-3205(90)90026-N","article-title":"Cyclosporine lowers seizure threshold in an experimental model of electroshock-induced seizures in Munich-Wistar rats","volume":"46","author":"Racusen","year":"1990","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib109","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib110","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1158\/1078-0432.CCR-06-0138","article-title":"Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice","volume":"12","author":"Reiriz","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib111","doi-asserted-by":"crossref","first-page":"21682","DOI":"10.1074\/jbc.273.34.21682","article-title":"Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans","volume":"273","author":"Ruckemann","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib112","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s12035-012-8314-5","article-title":"The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis","volume":"46","author":"Russo","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib113","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1111\/j.1600-6143.2006.01552.x","article-title":"FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia","volume":"6","author":"Salvadori","year":"2006","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib114","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.arcmed.2006.07.005","article-title":"Severe neurological events following liver transplantation","volume":"38","author":"Saner","year":"2007","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib115","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/01.tp.0000263332.65519.1f","article-title":"Impact of cyclosporine upon emotional and social behavior in mice","volume":"83","author":"Sato","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib116","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdf241","article-title":"Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients","volume":"13","author":"Schagen","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib117","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G","article-title":"Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma","volume":"85","author":"Schagen","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib118","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib119","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/11207350-000000000-00000","article-title":"Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis","volume":"25","author":"Scott","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib120","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib148","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbr.2009.10.009","article-title":"Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release","volume":"207","author":"Seigers","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib121","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.neubiorev.2010.09.006","article-title":"Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research","volume":"35","author":"Seigers","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib149","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbr.2007.08.004","article-title":"Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat","volume":"186","author":"Seigers","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib122","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbr.2009.02.025","article-title":"Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats","volume":"201","author":"Seigers","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib123","first-page":"3504","article-title":"A\u00a0direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells","volume":"60","author":"Sekulic","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib124","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3565(24)39073-1","article-title":"Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine","volume":"294","author":"Serkova","year":"2000","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib125","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0022-3565(24)38203-5","article-title":"Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in\u00a0vitro multinuclear NMR spectroscopy","volume":"289","author":"Serkova","year":"1999","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib126","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eplepsyres.2006.09.001","article-title":"Neuroprotectants FK-506 and cyclosporin A ameliorate the course of pilocarpine-induced seizures","volume":"73","author":"Setkowicz","year":"2007","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib127","first-page":"S14","article-title":"Mycophenolate mofetil","volume":"52","author":"Sollinger","year":"1995","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib128","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/ana.410310612","article-title":"Neurological complications following liver transplantation","volume":"31","author":"Stein","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib129","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1053-2498(00)00222-9","article-title":"Suggested guidelines for the use of tacrolimus in cardiac transplant recipients","volume":"20","author":"Taylor","year":"2001","journal-title":"J.\u00a0Heart Lung Transpl."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib130","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/01.tp.0000251718.95622.b3","article-title":"Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation","volume":"82","author":"Tedesco-Silva","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib131","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/01.tp.0000281385.26500.3b","article-title":"FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study","volume":"84","author":"Tedesco-Silva","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib132","first-page":"230386","article-title":"Cyclosporine: a review","volume":"2012","author":"Tedesco","year":"2012","journal-title":"J.\u00a0Transpl."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib133","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s10620-006-8012-0","article-title":"Neuropsychiatric complications after liver transplantation: role of immunosuppression and hepatitis C","volume":"51","author":"Tombazzi","year":"2006","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib134","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1253\/circj.CJ-13-0296","article-title":"Present status and future perspectives of heart transplantation","volume":"77","author":"Toyoda","year":"2013","journal-title":"Circ. J."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1034\/j.1600-0609.2001.t01-1-00440.x","article-title":"Clinical findings and magnetic resonance imaging in severe cyclosporine-related neurotoxicity after allogeneic bone marrow transplantation","volume":"67","author":"Trullemans","year":"2001","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib136","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10519-012-9571-9","article-title":"Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57BL\/6 mice","volume":"43","author":"Tsai","year":"2013","journal-title":"Behav. Genet."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib137","first-page":"281","article-title":"Immunosuppressive drugs after solid organ transplantation","volume":"71","author":"van Sandwijk","year":"2013","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib138","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J.\u00a0Antibiot. (Tokyo)"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib139","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0091-3057(97)00467-X","article-title":"Cyclosporine A affects open field behavior in DA rats","volume":"60","author":"von Horsten","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib140","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1002\/cncr.25098","article-title":"Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer","volume":"116","author":"Wefel","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib141","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1191\/1352458502ms790oa","article-title":"Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects","volume":"8","author":"Weiner","year":"2002","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib142","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/anr.1780320616","article-title":"Central nervous system toxicity associated with weekly low-dose methotrexate treatment","volume":"32","author":"Wernick","year":"1989","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib143","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/jlts.2001.27475","article-title":"Neurotoxicity of immunosuppressive drugs","volume":"7","author":"Wijdicks","year":"2001","journal-title":"Liver Transpl."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib144","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nlm.2010.01.006","article-title":"Cyclophosphamide impairs hippocampus-dependent learning and memory in adult mice: possible involvement of hippocampal neurogenesis in chemotherapy-induced memory deficits","volume":"93","author":"Yang","year":"2010","journal-title":"Neurobiol. Learn Mem."},{"key":"10.1016\/j.neuropharm.2014.12.008_bib145","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00213-012-2823-9","article-title":"Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway","volume":"225","author":"Yu","year":"2013","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2014.12.008_bib146","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1191\/1352458505ms1172sr","article-title":"One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis","volume":"11","author":"Zephir","year":"2005","journal-title":"Mult. Scler."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814004523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814004523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T16:29:01Z","timestamp":1747240141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390814004523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":149,"alternative-id":["S0028390814004523"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.12.008","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurobehavioral consequences of small molecule-drug immunosuppression","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}